论文部分内容阅读
目的观察孟鲁司特联合倍氯米松治疗对青春期前哮喘儿童骨密度的影响。方法选取医院收治的青春期前哮喘儿童120例为研究对象,随机分为观察组和对照组,每组60例。对照组采用孟鲁司特治疗,观察采用孟鲁司特联合倍氯米松治疗,观察比较2组治疗前后的骨密度。结果治疗后观察组脊柱骨密度低于对照组(P<0.01);前臂远端、前臂近端、股骨近端的骨密度与对照组比较差异均无统计学意义(P>0.05)。结论孟鲁司特联合倍氯米松治疗青春期前哮喘儿童,可对患儿脊柱骨密度产生影响,建议医师合理安排用药剂量和用药时间。
Objective To observe the effect of montelukast combined with beclometasone on bone mineral density in preteen adolescent asthmatic children. Methods A total of 120 children with pre-adolescent asthma treated in our hospital were selected as study subjects and randomly divided into observation group and control group with 60 cases in each group. The control group was treated with montelukast, montelukast and beclomethasone were observed. The bone mineral density before and after treatment was observed and compared between the two groups. Results After treatment, the bone mineral density in the observation group was lower than that in the control group (P <0.01). There was no significant difference in BMD between the distal forearm, proximal forearm and proximal femur compared with the control group (P> 0.05). Conclusion Montelukast combined with beclomethasone in children with pre-adolescent asthma can affect the spine bone mineral density, and it is advisable for physicians to rationally arrange the dosage and duration of medication.